JP2023531251A5 - - Google Patents

Info

Publication number
JP2023531251A5
JP2023531251A5 JP2022580094A JP2022580094A JP2023531251A5 JP 2023531251 A5 JP2023531251 A5 JP 2023531251A5 JP 2022580094 A JP2022580094 A JP 2022580094A JP 2022580094 A JP2022580094 A JP 2022580094A JP 2023531251 A5 JP2023531251 A5 JP 2023531251A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
antibody
disease
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531251A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/066989 external-priority patent/WO2021259927A2/en
Publication of JP2023531251A publication Critical patent/JP2023531251A/ja
Publication of JP2023531251A5 publication Critical patent/JP2023531251A5/ja
Priority to JP2025252172A priority Critical patent/JP2026053445A/ja
Pending legal-status Critical Current

Links

JP2022580094A 2020-06-23 2021-06-22 抗ｃｄ２抗体 Pending JP2023531251A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025252172A JP2026053445A (ja) 2020-06-23 2025-12-16 抗ｃｄ２抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063042844P 2020-06-23 2020-06-23
US63/042,844 2020-06-23
US202163135381P 2021-01-08 2021-01-08
US63/135,381 2021-01-08
US202163182095P 2021-04-30 2021-04-30
US63/182,095 2021-04-30
PCT/EP2021/066989 WO2021259927A2 (en) 2020-06-23 2021-06-22 Anti-cd2 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025252172A Division JP2026053445A (ja) 2020-06-23 2025-12-16 抗ｃｄ２抗体

Publications (2)

Publication Number Publication Date
JP2023531251A JP2023531251A (ja) 2023-07-21
JP2023531251A5 true JP2023531251A5 (https=) 2024-07-16

Family

ID=76730545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580094A Pending JP2023531251A (ja) 2020-06-23 2021-06-22 抗ｃｄ２抗体
JP2025252172A Pending JP2026053445A (ja) 2020-06-23 2025-12-16 抗ｃｄ２抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025252172A Pending JP2026053445A (ja) 2020-06-23 2025-12-16 抗ｃｄ２抗体

Country Status (9)

Country Link
US (2) US20230365687A1 (https=)
EP (1) EP4168035A2 (https=)
JP (2) JP2023531251A (https=)
CN (1) CN116322766A (https=)
AU (1) AU2021298111A1 (https=)
BR (1) BR112022026429A2 (https=)
CA (1) CA3188130A1 (https=)
MX (1) MX2022016039A (https=)
WO (1) WO2021259927A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023224980A1 (en) * 2022-05-17 2023-11-23 The Uab Research Foundation Methods and compositions for treating or preventing inflammatory skin disorders
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024079046A1 (en) * 2022-10-10 2024-04-18 Zelarion Malta Limited Anti-cd2 antibodies for type 1 diabetes
EP4673468A1 (en) 2023-03-01 2026-01-07 Zelarion Malta Limited Anti-cd2 antibodies for amyotrophic lateral sclerosis
KR20260016903A (ko) * 2023-05-30 2026-02-04 임노테크 쥐엠비에이치 항-cd2 단일 도메인 항체, 암 진단 및/또는 치료용 약학적 조성물 및 키트
WO2025207763A1 (en) * 2024-03-27 2025-10-02 Zelarion Malta Limited Method and composition for inducing tolerance of transplanted organ or tissue
WO2026052700A1 (en) 2024-09-05 2026-03-12 Zelarion Malta Limited Anti-cd2 antibodies for amyotrophic lateral sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327980T3 (es) * 1996-08-16 2009-11-05 Biotransplant, Inc Anticuerpo lo- d2a y sus usos para inhibir la activacion y la proli feracion de celulas t.
US6692743B1 (en) * 1998-05-08 2004-02-17 Universite Catholique De Louvain Apoptosis of naive human NK cells by crosslinking of their FcγRIIIa molecules with a rat IgG2b (LO-CD2a/BTI-322) or its IgG1 humanized monoclonal antibody
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
JP2013540731A (ja) * 2010-09-08 2013-11-07 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 安定かつ長期間の生着のための免疫抑制薬物組合せ
BR112020010816A2 (pt) * 2017-11-29 2020-11-10 Magenta Therapeutics, Inc. composições e métodos para a depleção de células de cd2+

Similar Documents

Publication Publication Date Title
JP2023531251A5 (https=)
JP6007316B2 (ja) 抗体製剤
RU2562874C1 (ru) Антитела против ох40 и способы их применения
RU2580012C2 (ru) Препарат антитела
JP6225142B2 (ja) 規則的に多量体化された免疫グロブリンＦｃ組成物を作製するための天然ヒトタンパク質断片の融合タンパク質
JP5597553B2 (ja) 疾患治療剤
DE60123238T2 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
US20070065437A1 (en) Anti-CD3 antibody formulations
AU2008207338B2 (en) Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex
JP2020528894A5 (https=)
JP2025000681A (ja) Ｂｔｌａ抗体
CN105492019A (zh) 抗体制剂和方法
CN106795220A (zh) 通过αβTCR结合多肽的多重施用的用于增强免疫抑制疗法的方法
IL314842A (en) Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
JP2006519228A (ja) 抗原に対し霊長類を免疫寛容化する組成物と方法
AU2002329423A1 (en) Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex
JP2008503593A (ja) 霊長類で寛容を誘導するための抗ｃｄ４抗体で最適化された投薬
TW202604957A (zh) 嵌合受體及其使用方法
NZ787392A (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2